Potential side effects include nausea, constipation, and gastrointestinal discomfort, particularly during early dose escalation
Serious treatment-related adverse events occurred in 20 of 125 patients (16%) in the cabozantinib group and 1 of 62 patients (2%) in the placebo group
Coskun T, Sloop KW, Loghin C, et al
To learn about other mild side effects, talk with your doctor or pharmacist or view the prescribing information for Ozempic, Wegovy, and Rybelsus
A meta-analysis of randomized controlled trials found that GLP-1 agonists in women with PCOS reduced body mass index, serum triglycerides, total testosterone, and waist circumference
Statements from the FDA About Ozempic On October 2, 2024, the FDA issued a postmarket safety information statement about concerns with unapproved versions of GLP-1 receptor agonists used for weight loss